Valstybinės Vaistų Kontrolės Tarnybos Prie Lietuvos Respublikos Sveikatos Apsaugos Ministerijos Viršininko Į S a K Y M a S

Total Page:16

File Type:pdf, Size:1020Kb

Valstybinės Vaistų Kontrolės Tarnybos Prie Lietuvos Respublikos Sveikatos Apsaugos Ministerijos Viršininko Į S a K Y M a S VALSTYBINĖS VAISTŲ KONTROLĖS TARNYBOS PRIE LIETUVOS RESPUBLIKOS SVEIKATOS APSAUGOS MINISTERIJOS VIRŠININKO Į S A K Y M A S DĖL VALSTYBINĖS VAISTŲ KONTROLĖS TARNYBOS PRIE LIETUVOS RESPUBLIKOS SVEIKATOS APSAUGOS MINISTERIJOS VIRŠININKO 2006 M. LAPKRIČIO 2 D. ĮSAKYMO NR. 1A-658 „DĖL TARPTAUTINIŲ PREKĖS ŽENKLU NEREGISTRUOTŲ VAISTINIŲ MEDŽIAGŲ PAVADINIMŲ ATITIKMENŲ LIETUVIŲ KALBA SĄRAŠO PATVIRTINIMO“ PAKEITIMO 2013 m. gegužės 2 d. Nr. (1.4)1A-480 Vilnius Atsižvelgdamas į Pasaulio sveikatos organizacijos 2013 m. paskelbtą 69-ąjį Rekomenduojamų tarptautinių prekės ženklu neregistruotų vaistinių medžiagų pavadinimų (INN) sąrašą, p a k e i č i u Tarptautinių prekės ženklu neregistruotų vaistinių medžiagų pavadinimų atitikmenų lietuvių kalba sąrašą, patvirtintą Valstybinės vaistų kontrolės tarnybos prie Lietuvos Respublikos sveikatos apsaugos ministerijos viršininko 2006 m. lapkričio 2 d. įsakymu Nr. 1A-658 „Dėl Tarptautinių prekės ženklu neregistruotų vaistinių medžiagų pavadinimų atitikmenų lietuvių kalba sąrašo patvirtinimo“ (Žin., 2006, Nr. 119-4557; 2007, Nr. 13-519; 2008, Nr. 24-896; 2010, Nr. 152-7773; 2011, Nr. 56-2700, Nr. 159-7553; 2012, Nr. 53-2664, Nr. 113-5776): 1. Papildau nauja eilute, kurią po eilutės „Actodigin Aktodiginas Actodiginum“ išdėstau taip: „Actoxumab Aktoksumabas Actoxumabum“ 2. Papildau nauja eilute, kurią po eilutės „Alacizumab pegol Alacizumabas pegolas Alacizumabum pegolum“ išdėstau taip: „Aladorian Aladorianas Aladorianum“ 3. Papildau nauja eilute, kurią po eilutės „Alipogene tiparvovec Alipogenas tiparvovekas Alipogenum tiparvovecum“ išdėstau taip: „Alirocumab Alirokumabas Alirocumabum“ 4. Papildau nauja eilute, kurią po eilutės „Antithrombin alfa Antitrombinas alfa Antithrombinum alfa“ išdėstau taip: „Antithrombin gamma Antitrombinas gama Antithrombinum gamma“ 5. Papildau nauja eilute, kurią po eilutės „Astromicin Astromicinas Astromicinum“ išdėstau taip: „Asudemotide Asudemotidas Asudemotidum“ 6. Papildau nauja eilute, kurią po eilutės „Auranofin Auranofinas Auranofinum“ išdėstau taip: „Auriclosene Auriklozenas Auriclosenum“ 7. Papildau nauja eilute, kurią po eilutės „Avasimibe Avazimibas Avasimibum“ išdėstau taip: „Avatrombopag Avatrombopagas Avatrombopagum“ 8. Papildau nauja eilute, kurią po eilutės „Balsalazide Balsalazidas Balsalazidum“ išdėstau taip: „Balugrastim Balugrastimas Balugrastimum“ 9. Papildau nauja eilute, kurią po eilutės „Bardoxolone Bardoksolonas Bardoxolonum“ išdėstau taip: „Baricitinib Baricitinibas Baricitinibum“ 10. Papildau nauja eilute, kurią po eilutės „Bevasiranib Bevaziranibas Bevasiranibum“ išdėstau taip: „Bevenopran Bevenopranas Bevenopranum“ 11. Papildau nauja eilute, kurią po eilutės „Bezitramide Bezitramidas Bezitramidum“ išdėstau taip: „Bezlotoxumab Bezlotoksumabas Bezlotoxumabum“ 12. Papildau nauja eilute, kurią po eilutės „Biricodar Birikodaras Biricodarum“ išdėstau taip: „Birinapant Birinapantas Birinapantum“ 13. Papildau nauja eilute, kurią po eilutės „Blinatumomab Blinatumomabas Blinatumomabum“ išdėstau taip: „Blisibimod Blisibimodas Blisibimodum“ 14. Papildau nauja eilute, kurią po eilutės „Burixafor Buriksaforas Burixaforum“ išdėstau taip: „Burlulipase Burlulipazė Burlulipasum“ 15. Papildau nauja eilute, kurią po eilutės „Cebaracetam Cebaracetamas Cebaracetamum“ išdėstau taip: „Cebranopadol Cebranopadolas Cebranopadolum“ 16. Papildau nauja eilute, kurią po eilutės „Cinchophen Cinchofenas Cinchophenum“ išdėstau taip: „Cindunistat Cindunistatas Cindunistatum“ 17. Papildau nauja eilute, kurią po eilutės „Clavulanic acid Klavulano rūgštis Acidum clavulanicum“ išdėstau taip: „Clazakizumab Klazakizumabas Clazakizumabum“ 18. Papildau nauja eilute, kurią po eilutės „Cobicistat Kobicistatas Cobicistatum“ išdėstau taip: „Cobimetinib Kobimetinibas Cobimetinibum“ 19. Papildau nauja eilute, kurią po eilutės „Crilvastatin Krilvastatinas Crilvastatinum“ išdėstau taip: „Crisantaspase Krisantaspazė Crisantaspasum“ 20. Papildau nauja eilute, kurią po eilutės „Dactinomycin Daktinomicinas Dactinomycinum“ išdėstau taip: „Dactolisib Daktolisibas Dactolisibum“ 21. Papildau nauja eilute, kurią po eilutės „Daniquidone Danikvidonas Daniquidonum“ išdėstau taip: „Danirixin Daniriksinas Danirixinum“ 22. Papildau nauja eilute, kurią po eilutės „Dembrexine Dembreksinas Dembrexinum“ išdėstau taip: „Demcizumab Demcizumabas Demcizumabum“ 23. Papildau nauja eilute, kurią po eilutės „Elbanizine Elbanizinas Elbanizinum“ išdėstau taip: „Elbimilast Elbimilastas Elbimilastum“ 24. Papildau nauja eilute, kurią po eilutės „Eltrombopag Eltrombopagas Eltrombopagum“ išdėstau taip: „Elubrixin Elubriksinas Elubrixinum“ 25. Papildau nauja eilute, kurią po eilutės „Empagliflozin Empagliflozinas Empagliflozinum“ išdėstau taip: „Empegfilgrastim Empegfilgrastimas Empegfilgrastimum“ 26. Papildau nauja eilute, kurią po eilutės „Enloplatin Enloplatina Enloplatinum“ išdėstau taip: „Enobosarm Enobosarmas Enobosarmum“ 27. Papildau nauja eilute, kurią po eilutės „Enolicam Enolikamas Enolicamum“ išdėstau taip: „Enoticumab Enotikumabas Enoticumabum“ 28. Papildau nauja eilute, kurią po eilutės „Ensaculin Ensakulinas Ensaculinum“ išdėstau taip: „Ensereptide Ensereptidas Ensereptidum“ 29. Papildau nauja eilute, kurią po eilutės „Enzacamene Enzakamenas Enzacamenum“ išdėstau taip: „Enzalutamide Enzalutamidas Enzalutamidum“ 30. Papildau nauja eilute, kurią po eilutės „Ertiprotafib Ertiprotafibas Ertiprotafibum“ išdėstau taip: „Ertugliflozin Ertugliflozinas Ertugliflozinum“ 31. Papildau nauja eilute, kurią po eilutės „Etiracetam Etiracetamas Etiracetamum“ išdėstau taip: „Etirinotecan pegol Etirinotekanas pegolas Etirinotecanum pegolum“ 32. Papildau nauja eilute, kurią po eilutės „Everolimus Everolimuzas Everolimusum“ išdėstau taip: „Evogliptin Evogliptinas Evogliptinum“ 33. Papildau naujomis eilutėmis, kurias po eilutės „Fasidotril Fazidotrilis Fasidotrilum“ išdėstau taip: „Fasiglifam Fasiglifamas Fasiglifamum Fasinumab Fasinumabas Fasinumabum“ 34. Papildau nauja eilute, kurią po eilutės „Firocoxib Firokoksibas Firocoxibum“ išdėstau taip: „Firtecan pegol Firtekanas pegolas Firtecanum pegolum“ 35. Papildau nauja eilute, kurią po eilutės „Fluradoline Fluradolinas Fluradolinum“ išdėstau taip: „Fluralaner Fluralaneras Fluralanerum“ 36. Papildau nauja eilute, kurią po eilutės „Fusidic acid Fuzido rūgštis Acidum fusidicum“ išdėstau taip: „Futuximab Futuksimabas Futuximabum“ 37. Papildau nauja eilute, kurią po eilutės „Gimeracil Gimeracilas Gimeracilum“ išdėstau taip: „Giminabant Giminabantas Giminabantum“ 38. Papildau nauja eilute, kurią po eilutės „Golotimod Golotimodas Golotimodum“ išdėstau taip: „Golvatinib Golvatinibas Golvatinibum“ 39. Papildau nauja eilute, kurią po eilutės „Ibrotamide Ibrotamidas Ibrotamidum“ išdėstau taip: „Ibrutinib Ibrutinibas Ibrutinibum“ 40. Papildau nauja eilute, kurią po eilutės „Idebenone Idebenonas Idebenonum“ išdėstau taip: „Idelalisib Idelalisibas Idelalisibum“ 41. Papildau nauja eilute, kurią po eilutės „Imexon Imeksonas Imexonum“ išdėstau taip: „Imgatuzumab Imgatuzumabas Imgatuzumabum“ 42. Papildau nauja eilute, kurią po eilutės „Insulin lispro Insulinas lispro Insulinum lisprum“ išdėstau taip: „Insulin peglispro Insulinas peglispro Insulinum peglisprum“ 43. Papildau nauja eilute, kurią po eilutės „Lamotrigine Lamotriginas Lamotriginum“ išdėstau taip: „Lampalizumab Lampalizumabas Lampalizumabum“ 44. Papildau nauja eilute, kurią po eilutės „Latanoprost Latanoprostas Latanoprostum“ išdėstau taip: „Latanoprostene bunod Latanoprostenas bunodas Latanoprostenum bunodum“ 45. Papildau nauja eilute, kurią po eilutės „Latrepirdine Latrepirdinas Latrepirdinum“ išdėstau taip: „Latromotide Latromotidas Latromotidum“ 46. Papildau naujomis eilutėmis, kurias po eilutės „Lificiguat Lificiguatas Lificiguatum“ išdėstau taip: „Lifitegrast Lifitegrastas Lifitegrastum Ligelizumab Ligelizumabas Ligelizumabum“ 47. Papildau nauja eilute, kurią po eilutės „Lirexapride Lireksapridas Lirexapridum“ išdėstau taip: „Lirilumab Lirilumabas Lirilumabum“ 48. Papildau nauja eilute, kurią po eilutės „Lomevactone Lomevaktonas Lomevactonum“ išdėstau taip: „Lomibuvir Lomibuviras Lomibuvirum“ 49. Papildau nauja eilute, kurią po eilutės „Lucimycin Lucimicinas Lucimycinum“ išdėstau taip: „Lucitanib Lucitanibas Lucitanibum“ 50. Papildau nauja eilute, kurią po eilutės „Molsidomine Molsidominas Molsidominum“ išdėstau taip: „Momelotinib Momelotinibas Momelotinibum“ 51. Papildau nauja eilute, kurią po eilutės „Nivocasan Nivokasanas Nivocasanum“ išdėstau taip: „Nivolumab Nivolumabas Nivolumabum“ 52. Papildau nauja eilute, kurią po eilutės „Ocaperidone Okaperidonas Ocaperidonum“ išdėstau taip: „Ocaratuzumab Okaratuzumabas Ocaratuzumabum“ 53. Papildau nauja eilute, kurią po eilutės „Omapatrilat Omapatrilatas Omapatrilatum“ išdėstau taip: „Omarigliptin Omarigliptinas Omarigliptinum“ 54. Papildau nauja eilute, kurią po eilutės „Oprelvekin Oprelvekinas Oprelvekinum“ išdėstau taip: „Oprozomib Oprozomibas Oprozomibum“ 55. Papildau nauja eilute, kurią po eilutės „Ortetamine Ortetaminas Ortetaminum“ išdėstau taip: „Orticumab Ortikumabas Orticumabum“ 56. Papildau nauja eilute, kurią po eilutės „Parsalmide Parsalmidas Parsalmidum“ išdėstau taip: „Parsatuzumab Parsatuzumabas Parsatuzumabum“ 57. Papildau nauja eilute, kurią po eilutės „Pecocycline Pekociklinas Pecocyclinum“ išdėstau taip: „Pefcalcitol Pefkalcitolis Pefcalcitolum“ 58. Papildau nauja eilute, kurią po eilutės „Perafensine Perafenzinas Perafensinum“ išdėstau taip: „Perakizumab Perakizumabas Perakizumabum“ 59. Papildau nauja eilute, kurią po eilutės „Picotrin Pikotrinas Picotrinum“ išdėstau
Recommended publications
  • Print PDF Opens in a New Window
    CADTH ISSUES IN EMERGING HEALTH TECHNOLOGIES Informing Decisions About New Health Technologies Issue July 173 2018 Monoclonal Antibodies for Osteoarthritis of the Hip or Knee Image courtesy of iStock CADTH ISSUES IN EMERGING HEALTH TECHNOLOGIES 1 Authors: Sirjana Pant, Ke Xin Li, Melissa Severn Cite As: Monoclonal Antibodies for Osteoarthritis of the Hip or Knee. Ottawa: CADTH; 2018. (CADTH issues in emerging health technologies; issue 173). Acknowledgments: CADTH would like to acknowledge the contribution of Dr. Tom Appleton, MD, PhD, FRCPC, Assistant Professor, Rheumatologist; Department of Medicine, Department of Physiology and Pharmacology, The University of Western Ontario; Clinician Scientist, Lawson Health Research Institute; The Rheumatology Centre, St. Joseph’s Health Care London; for his review of the draft version of this bulletin. ISSN: 1488-6324 (online) Disclaimer: The information in this document is intended to help Canadian health care decision-makers, health care professionals, health systems leaders, and policy- makers make well-informed decisions and thereby improve the quality of health care services. While patients and others may access this document, the document is made available for informational purposes only and no representations or warranties are made with respect to its fitness for any particular purpose. The information in this document should not be used as a substitute for professional medical advice or as a substitute for the application of clinical judgment in respect of the care of a particular patient or other professional judgment in any decision-making process. The Canadian Agency for Drugs and Technologies in Health (CADTH) does not endorse any information, drugs, therapies, treatments, products, processes, or services.
    [Show full text]
  • Strategies to Enhance Monoclonal Antibody Uptake and Distribution in Solid Tumors
    Cancer Biol Med 2021. doi: 10.20892/j.issn.2095-3941.2020.0704 REVIEW Strategies to enhance monoclonal antibody uptake and distribution in solid tumors Brandon M. Bordeau, Joseph P. Balthasar Department of Pharmaceutical Science, University at Buffalo, Buffalo, NY 14214, USA ABSTRACT Despite the significant resources dedicated to the development of monoclonal antibody (mAb) therapies for solid tumors, the clinical success, thus far, has been modest. Limited efficacy of mAb in solid tumors likely relates to unique aspects of tumor physiology. Solid tumors have an aberrant vasculature and a dense extracellular matrix that slow both the convective and diffusive transport of mAbs into and within tumors. For mAbs that are directed against cellular antigens, high antigen expression and rapid antigen turnover can result in perivascular cells binding to and eliminating a significant amount of extravasated mAb, limiting mAb distribution to portions of the tumor that are distant from functional vessels. Many preclinical investigations have reported strategies to improve mAb uptake and distribution; however, to our knowledge, none have translated into the clinic. Here, we provide an overview of several barriers in solid tumors that limit mAb uptake and distribution and discuss approaches that have been utilized to overcome these barriers in preclinical studies. KEYWORDS Solid tumors; antibody uptake and distribution; monoclonal antibody; antibody–drug conjugate Introduction Currently, monoclonal antibodies (mAbs) are heralded as the “magic bullets” that Ehrlich envisioned, and in many cases, the In 1900, Paul Ehrlich developed the receptor theory, which moniker is well deserved. Antibodies can bind most substances was built on the foundational hypothesis that toxins, nutri- with high affinity and high selectivity and are used for the treat- ents, and drugs exert their observed effect through binding to ment of many diseases.
    [Show full text]
  • Predictive QSAR Tools to Aid in Early Process Development of Monoclonal Antibodies
    Predictive QSAR tools to aid in early process development of monoclonal antibodies John Micael Andreas Karlberg Published work submitted to Newcastle University for the degree of Doctor of Philosophy in the School of Engineering November 2019 Abstract Monoclonal antibodies (mAbs) have become one of the fastest growing markets for diagnostic and therapeutic treatments over the last 30 years with a global sales revenue around $89 billion reported in 2017. A popular framework widely used in pharmaceutical industries for designing manufacturing processes for mAbs is Quality by Design (QbD) due to providing a structured and systematic approach in investigation and screening process parameters that might influence the product quality. However, due to the large number of product quality attributes (CQAs) and process parameters that exist in an mAb process platform, extensive investigation is needed to characterise their impact on the product quality which makes the process development costly and time consuming. There is thus an urgent need for methods and tools that can be used for early risk-based selection of critical product properties and process factors to reduce the number of potential factors that have to be investigated, thereby aiding in speeding up the process development and reduce costs. In this study, a framework for predictive model development based on Quantitative Structure- Activity Relationship (QSAR) modelling was developed to link structural features and properties of mAbs to Hydrophobic Interaction Chromatography (HIC) retention times and expressed mAb yield from HEK cells. Model development was based on a structured approach for incremental model refinement and evaluation that aided in increasing model performance until becoming acceptable in accordance to the OECD guidelines for QSAR models.
    [Show full text]
  • Deciphering Molecular Mechanisms and Prioritizing Therapeutic Targets in Cardio-Oncology
    Figure 1. This is a pilot view to explore the potential of EpiGraphDB to inform us about proteins that are linked to the pathophysiology of cancer and cardiovascular disease (CVD). For each cancer type (pink diamonds), we searched for cancer related proteins (light blue circles) that interact with other proteins identified as protein quantitative trait loci (pQTLs) for CVD (red diamonds for pathologies, orange triangles for risk factors). These pQTLs can be acting in cis (solid lines) or trans-acting (dotted lines). Proteins can interact either directly, a protein-protein interaction (dotted blue edges), or through the participation in the same pathway (red parallel lines). Shared pathways are represented with blue hexagons. We also queried which of these proteins are targeted by existing drugs. We found that the cancer drug cetuximab (yellow circle) inhibits EGFR. Other potential drugs are depicted in light brown hexagonal meta-nodes that are detailed below. Deciphering molecular mechanisms and prioritizing therapeutic targets in cardio-oncology Pau Erola1,2, Benjamin Elsworth1,2, Yi Liu2, Valeriia Haberland2 and Tom R Gaunt1,2,3 1 CRUK Integrative Cancer Epidemiology Programme; 2 MRC Integrative Epidemiology Unit, University of Bristol; 3 The Alan Turing Institute Cancer and cardiovascular disease (CVD) make by far the immense What is EpiGraphDB? contribution to the totality of human disease burden, and although mortality EpiGraphDB is an analytical platform and graph database that aims to is declining the number of those living with the disease shows little address the necessity of innovative and scalable approaches to harness evidence of change (Bhatnagar et al., Heart, 2016).
    [Show full text]
  • REGENERON PHARMACEUTICALS, INC. (Exact Name of Registrant As Specified in Charter)
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 9, 2017 (February 9, 2017) REGENERON PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) New York 000-19034 13-3444607 (State or other jurisdiction (Commission (IRS Employer of Incorporation) File No.) Identification No.) 777 Old Saw Mill River Road, Tarrytown, New York 10591-6707 (Address of principal executive offices, including zip code) (914) 847-7000 (Registrant's telephone number, including area code) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Item 2.02 Results of Operations and Financial Condition. On February 9, 2017, Regeneron Pharmaceuticals, Inc. issued a press release announcing its financial and operating results for the quarter and year ended December 31, 2016. A copy of the press release is being furnished to the Securities and Exchange Commission as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference to this Item 2.02.
    [Show full text]
  • PDCO Minutes of Meeting 18-21 May 2021
    21 May 2021 EMA/PDCO/298607/2021 Human Medicines Division Paediatric Committee (PDCO) Minutes for the meeting on 18-21 May 2021 Chair: Koenraad Norga – Vice-Chair: Sabine Scherer Virtual Meeting Disclaimers Some of the information contained in this set of minutes is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. Additional details on some of these procedures will be published in the PDCO Committee meeting reports (after the PDCO Opinion is adopted), and on the Opinions and decisions on paediatric investigation plans webpage (after the EMA Decision is issued). Of note, this set of minutes is a working document primarily designed for PDCO members and the work the Committee undertakes. Note on access to documents Some documents mentioned in the minutes cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to on-going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006). Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union © European Medicines Agency, 2021.
    [Show full text]
  • Classification Decisions Taken by the Harmonized System Committee from the 47Th to 60Th Sessions (2011
    CLASSIFICATION DECISIONS TAKEN BY THE HARMONIZED SYSTEM COMMITTEE FROM THE 47TH TO 60TH SESSIONS (2011 - 2018) WORLD CUSTOMS ORGANIZATION Rue du Marché 30 B-1210 Brussels Belgium November 2011 Copyright © 2011 World Customs Organization. All rights reserved. Requests and inquiries concerning translation, reproduction and adaptation rights should be addressed to [email protected]. D/2011/0448/25 The following list contains the classification decisions (other than those subject to a reservation) taken by the Harmonized System Committee ( 47th Session – March 2011) on specific products, together with their related Harmonized System code numbers and, in certain cases, the classification rationale. Advice Parties seeking to import or export merchandise covered by a decision are advised to verify the implementation of the decision by the importing or exporting country, as the case may be. HS codes Classification No Product description Classification considered rationale 1. Preparation, in the form of a powder, consisting of 92 % sugar, 6 % 2106.90 GRIs 1 and 6 black currant powder, anticaking agent, citric acid and black currant flavouring, put up for retail sale in 32-gram sachets, intended to be consumed as a beverage after mixing with hot water. 2. Vanutide cridificar (INN List 100). 3002.20 3. Certain INN products. Chapters 28, 29 (See “INN List 101” at the end of this publication.) and 30 4. Certain INN products. Chapters 13, 29 (See “INN List 102” at the end of this publication.) and 30 5. Certain INN products. Chapters 28, 29, (See “INN List 103” at the end of this publication.) 30, 35 and 39 6. Re-classification of INN products.
    [Show full text]
  • Shadows Cast Over JAK Class Following Xeljanz Mortality Signal
    1 March 2019 No. 3944 Scripscrip.pharmaintelligence.informa.com Pharma intelligence | informa to evaluate cardiovascular safety for both doses against an active comparator, as opposed to relying on post-marketing event reporting. On Feb. 19, Pfizer reported some results from this trial – A3921133 — and the news was alarming. Unlike prior studies, this tri- al enrolled patients who were age 50 and up and had at least one cardiovascular risk factor, the company noted. The study test- ed Xeljanz on top of background metho- trexate and included an arm with patients on a tumor necrosis factor inhibitor (TNFi). Results were monitored by an external Rheumatology Drug Safety Monitoring Board (DSMB) “Based on the most recent analysis of the ongoing A3921133 study, the DSMB observed that patients treated with to- facitinib 10 mg twice daily had a statisti- cally and clinically important difference Shadows Cast Over JAK Class in the occurrence of pulmonary em- bolism, compared with patients in this Following Xeljanz Mortality Signal study who were treated with a TNFi. The DSMB also noted an increase in overall EMILY HAYES [email protected] mortality in the 10 mg twice daily treat- ment group compared to the tofacitinib he cardiovascular risks seen with a in 2016. (Also see “PIPELINE WATCH – 10 5 mg twice daily and TNFi treatment higher-than-approved dose of Pfiz- Approvals, Two Breakthroughs And A Re- arms,” Pfizer said. T er Inc.’s Janus kinase (JAK) inhibitor fusal To File Letter” - Scrip, 1 Mar, 2016.) The This safety signal has not been picked Xeljanz in a long-term rheumatoid arthri- drug’s initial clearance came with a lot of up in adverse event reporting systems, tis study required by the US FDA have cast safety baggage.
    [Show full text]
  • Primary and Acquired Resistance to Immunotherapy in Lung Cancer: Unveiling the Mechanisms Underlying of Immune Checkpoint Blockade Therapy
    cancers Review Primary and Acquired Resistance to Immunotherapy in Lung Cancer: Unveiling the Mechanisms Underlying of Immune Checkpoint Blockade Therapy Laura Boyero 1 , Amparo Sánchez-Gastaldo 2, Miriam Alonso 2, 1 1,2,3, , 1,2, , José Francisco Noguera-Uclés , Sonia Molina-Pinelo * y and Reyes Bernabé-Caro * y 1 Institute of Biomedicine of Seville (IBiS) (HUVR, CSIC, Universidad de Sevilla), 41013 Seville, Spain; [email protected] (L.B.); [email protected] (J.F.N.-U.) 2 Medical Oncology Department, Hospital Universitario Virgen del Rocio, 41013 Seville, Spain; [email protected] (A.S.-G.); [email protected] (M.A.) 3 Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), 28029 Madrid, Spain * Correspondence: [email protected] (S.M.-P.); [email protected] (R.B.-C.) These authors contributed equally to this work. y Received: 16 November 2020; Accepted: 9 December 2020; Published: 11 December 2020 Simple Summary: Immuno-oncology has redefined the treatment of lung cancer, with the ultimate goal being the reactivation of the anti-tumor immune response. This has led to the development of several therapeutic strategies focused in this direction. However, a high percentage of lung cancer patients do not respond to these therapies or their responses are transient. Here, we summarized the impact of immunotherapy on lung cancer patients in the latest clinical trials conducted on this disease. As well as the mechanisms of primary and acquired resistance to immunotherapy in this disease. Abstract: After several decades without maintained responses or long-term survival of patients with lung cancer, novel therapies have emerged as a hopeful milestone in this research field.
    [Show full text]
  • 2017 Immuno-Oncology Medicines in Development
    2017 Immuno-Oncology Medicines in Development Adoptive Cell Therapies Drug Name Organization Indication Development Phase ACTR087 + rituximab Unum Therapeutics B-cell lymphoma Phase I (antibody-coupled T-cell receptor Cambridge, MA www.unumrx.com immunotherapy + rituximab) AFP TCR Adaptimmune liver Phase I (T-cell receptor cell therapy) Philadelphia, PA www.adaptimmune.com anti-BCMA CAR-T cell therapy Juno Therapeutics multiple myeloma Phase I Seattle, WA www.junotherapeutics.com Memorial Sloan Kettering New York, NY anti-CD19 "armored" CAR-T Juno Therapeutics recurrent/relapsed chronic Phase I cell therapy Seattle, WA lymphocytic leukemia (CLL) www.junotherapeutics.com Memorial Sloan Kettering New York, NY anti-CD19 CAR-T cell therapy Intrexon B-cell malignancies Phase I Germantown, MD www.dna.com ZIOPHARM Oncology www.ziopharm.com Boston, MA anti-CD19 CAR-T cell therapy Kite Pharma hematological malignancies Phase I (second generation) Santa Monica, CA www.kitepharma.com National Cancer Institute Bethesda, MD Medicines in Development: Immuno-Oncology 1 Adoptive Cell Therapies Drug Name Organization Indication Development Phase anti-CEA CAR-T therapy Sorrento Therapeutics liver metastases Phase I San Diego, CA www.sorrentotherapeutics.com TNK Therapeutics San Diego, CA anti-PSMA CAR-T cell therapy TNK Therapeutics cancer Phase I San Diego, CA www.sorrentotherapeutics.com Sorrento Therapeutics San Diego, CA ATA520 Atara Biotherapeutics multiple myeloma, Phase I (WT1-specific T lymphocyte South San Francisco, CA plasma cell leukemia www.atarabio.com
    [Show full text]
  • Looking for Therapeutic Antibodies in Next Generation Sequencing Repositories
    bioRxiv preprint doi: https://doi.org/10.1101/572958; this version posted March 10, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. Title: Looking for Therapeutic Antibodies in Next Generation Sequencing Repositories. Authors: Konrad Krawczyk1*, Matthew Raybould2, Aleksandr Kovaltsuk2, Charlotte M. Deane2 1 NaturalAntibody, Hamburg, Germany 2 Oxford University Department of Statistics, Oxford, UK *Correspondence to [email protected] Abstract: Recently it has become possible to query the great diversity of natural antibody repertoires using Next Generation Sequencing (NGS). These methods are capable of producing millions of sequences in a single experiment. Here we compare Clinical Stage Therapeutic antibodies to the ~1b sequences from 60 independent sequencing studies in the Observed Antibody Space Database. Of the 242 post Phase I antibodies, we find 16 with sequence identity matches of 95% or better for both heavy and light chains. There are also 54 perfect matches to therapeutic CDR-H3 regions in the NGS outputs, suggesting a nontrivial amount of convergence between naturally observed sequences and those developed artificially. This has potential implications for both the discovery of antibody therapeutics and the legal protection of commercial antibodies. Introduction Antibodies are proteins in jawed vertebrates that recognize noxious molecules (antigens) for elimination. An organism expresses millions of diverse antibodies to increase the chances that some of them will be able to bind the foreign antigen, initiating the adaptive immune response.
    [Show full text]
  • Tables-Of-Phase-3-Mabs.Pdf
    Table 3. Monoclonal antibodies in Phase 2/3 or 3 clinical studies for cancer indications Most advanced Primary sponsoring company INN or code name Molecular format Target(s) phase Phase 3 indications Therapeutic area Janssen Research & Development, LLC JNJ-56022473 Humanized mAb CD123 Phase 2/3 Acute myeloid leukemia Cancer Murine IgG1, Actinium Pharmaceuticals Iomab-B radiolabeled CD45 Phase 3 Acute myeloid leukemia Cancer Humanized IgG1, Seattle Genetics Vadastuximab talirine ADC CD33 Phase 3 Acute myeloid leukemia Cancer TG Therapeutics Ublituximab Chimeric IgG1 CD20 Phase 3 Chronic lymphocytic leukemia Cancer Xencor XMAB-5574, MOR208 Humanized IgG1 CD19 Phase 2/3 Diffuse large B-cell lymphoma Cancer Moxetumomab Murine IgG1 dsFv, AstraZeneca/MedImmune LLC pasudotox immunotoxin CD22 Phase 3 Hairy cell leukemia Cancer Humanized scFv, Viventia Bio Oportuzumab monatox immunotoxin EpCAM Phase 3 Bladder cancer Cancer scFv-targeted liposome containing Merrimack Pharmaceuticals MM-302 doxorubicin HER2 Phase 2/3 Breast cancer Cancer MacroGenics Margetuximab Chimeric IgG1 HER2 Phase 3 Breast cancer Cancer Gastric cancer or gastroesophageal junction Gilead Sciences GS-5745 Humanized IgG4 MMP9 Phase 3 adenocarcinoma; ulcerative colitis (Phase 2/3) Cancer; Immune-mediated disorders Depatuxizumab Humanized IgG1, AbbVie mafodotin ADC EGFR Phase 2/3 Glioblastoma Cancer AstraZeneca/MedImmune LLC Tremelimumab Human IgG2 CTLA4 Phase 3 NSCLC, head & neck cancer, bladder cancer Cancer NSCLC, head & neck cancer, bladder cancer, breast AstraZeneca/MedImmune
    [Show full text]